Project Grant R13CA254055

This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $456,103 in funding to The Feinstein Institutes for Medical Research to develop integrated risk models for endometrial cancer. The project aims to enhance early detection of endometrial cancer by determining the burden of rare genetic risk factors and creating predictive models that integrate genetic and non-genetic factors such as BMI, diabetes, and PCOS. The research will...

Federal Grant Award Summary: Advancing Hormone Therapy for Endometrial Cancer The National Cancer Institute (NCI) awarded the University of New Mexico Health Sciences Center a $2.8 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 8, 2025, with a project completion date of July 31, 2030. This multi-institutional Program Project (P01) grant seeks to improve clinical outcomes for patients with uterine endometrial cancer and atypical endometrial...

This federal Project Grant award from the Defense Health Agency provides $1,555,000.00 to the University of North Carolina at Chapel Hill to support their research project titled "TARGETING OBESITY VIA DIET AND DRUGS FOR THE TREATMENT OF ENDOMETRIAL CANCER". The award is funded under the Military Medical Research and Development (CFDA 12.420) federal grant program, which supports advanced biomedical research initiatives focused on transforming healthcare for military personnel and...

GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...

This Project Grant award of $491,975 from the Department of the Army Medical Command through its Military Medical Research and Development program (CFDA 12.420) will fund research into elucidating the roles of the extracellular matrix in epithelioid hemangioendothelioma progression. The Cleveland Clinic Foundation will utilize a novel genetically engineered mouse model to complete the aims of the project from September 1, 2021 to August 31, 2023. Albany Medical College will aid in several...

Federal Cooperative Agreement Summary The University of North Carolina at Chapel Hill received a $2.255 million Cooperative Agreement from the National Cancer Institute under the Cancer Centers Support Grants program (CFDA 93.397), awarded September 4, 2025, with completion targeted for July 31, 2030. This award establishes a Cancer Health Disparities Specialized Program of Research Excellence (SPORE) in endometrial cancer, addressing one of the largest health disparities in U.S. cancers. The...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $653,967 Project Grant to The University of Texas MD Anderson Cancer Center on March 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel therapeutic strategies targeting PPP2R1A mutations in gynecological cancers. The research deliverables focus on investigating the mechanistic basis by which PPP2R1A-mutated cancer cells demonstrate selective sensitivity to KAT6A (lysine acetyltransferase...

Grant Award Summary The National Cancer Institute (NCI) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a $404,974 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 1, 2025, through August 31, 2027. This award funds a comprehensive research initiative to evaluate the adoption, implementation, and maintenance of thermal ablation (TA) as a cervical precancer treatment within El Salvador's national health...

Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The research project investigates dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining BCL-2 (B-cell lymphoma-2) inhibition with CD123-directed natural killer (NK) cell engager immunotherapies. The research...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...